AstraZeneca looks to more than double new cancer drugs by 2030
AstraZeneca is aiming to more than double its portfolio of new cancer drugs by the end of this decade, seeking the top spot in the world''s most lucrative category of medicines.
AstraZeneca looks to more than double new cancer drugs by 2030
AstraZeneca is aiming to more than double its portfolio of new cancer drugs by the end of this decade, seeking the top spot in the world''s most lucrative category of medicines.